Pulmonary Embolism Therapeutics Market, By Treatment (Direct Oral Anticoagulants (DOACs), Low-Molecular-Weight Heparin (LMWH), Unfractionated Heparin, Vitamin K Antagonists, Thrombolytics and Others), By Route of Administration, By End User, By Country, and By Region Global Industry Analysis, Market Size, Market Share & Forecast from 2026-2033
|
Report ID
ANV5904
|
Published Date
August 2026
|
Pages
287
|
Industry
Healthcare
|
|
|
Base Year
2025
|
Historical Data
2019-2024
|
Delivery Timeline
24 Hour
|
REPORT HIGHLIGHT
Pulmonary Embolism Therapeutics Market size was valued at US$ 3,105.8 Million in 2025, expanding at a CAGR of 6.6% from 2026 to 2033.
The treatment of pulmonary embolism includes the use of drugs to reduce the coagulation ability of blood, thrombolytics to remove the clot, clot removal procedures, and various surgeries to re-establish blood flow in the lungs. Medication is the standard treatment for pulmonary embolism, but mechanical thrombectomy and catheter-based treatments are being considered for a growing number of moderate and high-risk patients. Additionally, hospitals are starting to form multidisciplinary pulmonary embolism response teams that can assess and treat patients with life-threatening pulmonary embolism. The 2025 study by the PERT Consortium includes 12,346 patients, out of which 2,958 received advanced treatments. This shows that the treatment of pulmonary embolism is shifting from a standardized approach to a more individualized one, based on the patient\'s needs.
Pulmonary Embolism Therapeutics Market- Market Dynamics
Risk-Stratified Care Is Reshaping Treatment Selection
There is a growing trend towards determining the intensity of treatment based on the level of risk in patients, rather than diagnoses. Multidisciplinary response models that involve emergency medicine, cardiology, pulmonary, vascular, and interventional disciplines are being formed to provide alternative treatments and rapid access to more intensive therapies when a high likelihood of deterioration is detected. The meta-analysis performed in 2025, which included 24 studies, revealed that overall mortality after PERT treatment was lower compared to conventional care, with an odds ratio of 0.72 and a higher utilization of advanced therapies. Its impact on the commercial landscape is profound, since the choice of treatment now depends more on catheter technology, hospital protocols, interventional expertise, evidence generation, and networks. Thus, coordinated management of PE has become a significant differentiator in therapy.
Pulmonary Embolism Therapeutics Market- Segmentation Analysis:
The Global Pulmonary Embolism Therapeutics Market is segmented on the basis of Treatment, Route of Administration, End User, and Region.
In terms of End User, Hospitals account for the primary end-user segment, as the Route of Administration, risk-factor analysis, introduction of anticoagulant therapy, fibrinolytic treatment, interventional catheterization, surgery, and intensive care usually require highly coordinated medical procedures. Specialized clinics are mostly involved in aftercare coordination, anticoagulant supervision, and home care, while the latter is rather a post-acute option than an acute care choice. According to a 2025 interhospital transfer study, catheterization was implemented in 32.3% of transferred patients versus 17.1% of those who entered directly from the community. This data illustrates how the procedural scope of hospitals affects interfacility transfer patterns. Hence, the competition within the end-user segment is mainly conditioned by the range of operations and expertise rather than the overall number of facilities.
Pulmonary Embolism Therapeutics Market- Geographical Insights
The United States is the fastest growing market for developing treatments for pulmonary embolism due to its high level of development of cardiovascular and interventional infrastructures for such procedures as mechanical thrombectomy and coordinated treatment of PE. The US has a developed base of device companies, academic institutions, and care providers, as well as regulatory and reimbursement systems to improve evidence generation and commercialization. According to the PERT Consortium\'s 2025 registry study, which included 48 US hospitals and 2,958 patients who received therapy with innovative techniques, clinicians in the United States continue to engage in an active dialogue about the development and use of medical devices. Thus, the US market is an important center for innovation and interaction for various medical devices that require a multidisciplinary approach and are used in the current treatment of PE.
The European market includes a large number of countries with different levels of cardiological care provision. The main feature of the European healthcare system is its segmented structure, which includes highly specialized hospitals, networks of national care providers, and cardiological services with unique competencies. The choice of intervention method in Europe is associated with reimbursement policies, access to surgical techniques, and clinical evidence rather than availability. According to the 2025 ESC cardiovascular statistics report, the data from 56 member states of the European Society of Cardiology, representing more than 900 million patients, were analyzed. Due to the complex structure of the healthcare system, the number of hospitals providing services for treating PE may vary from country to country. However, cardiologists in individual European countries continue to provide high-quality care with innovative techniques. In general, this region is characterized by a wide range of approaches to treatment, which is due to the segmentation of the hospital base.
Pulmonary Embolism Therapeutics Market- Competitive Landscape:
Competitive positioning trends for thrombectomy catheters are shifting towards showcasing combinations of clinical evidence, procedural pathways, and institutional adoption capability rather than individual device characteristics. Stryker\'s vascular division secured a dominant position in the field across peripheral interventional devices with the 2025 acquisition of Inari Medical, which saw the FlowTriever pulmonary embolism (PE) retrieval system added to its product suite. Meanwhile, Penumbra is set to report findings from its multicenter registry study for computer-assisted vacuum thrombectomy. The FDA\'s 2025 record for Symphony-PE cites the inclusion of 109 patients at 19 US sites in a prospective study. Evidence, consistency of supply, physician training, and overall breadth of offerings are becoming key differentiating factors as the clinical, economic, and procedural complexities around peripheral and pulmonary thrombectomy interventions become more prominent.
Recent Developments:
- In February 2025, Stryker completed the acquisition of Inari Medical. The deal merged FlowTriever, a pulmonary embolism mechanical thrombectomy platform, into Stryker\'s line, improving its peripheral vascular position and access to integrated venous thromboembolism technologies.
- In June 2025, Penumbra completed recruitment for the STORM-PE randomized controlled trial. This multicenter trial enrolled 100 patients and was conducted by comparing computer-assisted vacuum thrombectomy with anticoagulation against anticoagulation alone, increasing the body of evidence supporting the mechanical treatment of PE.
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL PULMONARY EMBOLISM THERAPEUTICS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
- Bayer AG
- Johnson & Johnson
- Pfizer Inc.
- Bristol Myers Squibb
- Daiichi Sankyo Co., Ltd.
- Sanofi
- Boehringer Ingelheim
- Viatris Inc.
- Novartis AG
- Eli Lilly and Company
- Amgen Inc.
- Astellas Pharma Inc.
- Hoffmann-La Roche Ltd.
- Gilead Sciences Inc.
- Takeda Pharmaceutical Company Limited
- Others
GLOBAL PULMONARY EMBOLISM THERAPEUTICS MARKET, BY TREATMENT- MARKET ANALYSIS, 2020 - 2033
- Direct Oral Anticoagulants (DOACs)
- Low-Molecular-Weight Heparin (LMWH)
- Unfractionated Heparin
- Vitamin K Antagonists
- Thrombolytics
- Others
GLOBAL PULMONARY EMBOLISM THERAPEUTICS MARKET, BY ROUTE OF ADMINISTATION- MARKET ANALYSIS, 2020 - 2033
- Oral
- Injectables
- Others
GLOBAL PULMONARY EMBOLISM THERAPEUTICS MARKET, BY END USER- MARKET ANALYSIS, 2020 - 2033
- Hospitals
- Specialty Clinics
- Retail Pharmacies
- Home Healthcare Providers
- Others
GLOBAL PULMONARY EMBOLISM THERAPEUTICS MARKET, BY REGION- MARKET ANALYSIS, 2020 - 2033
North America
- U.S.
- Canada
Europe
- Germany
- UK
- France
- Italy
- Spain
- The Netherlands
- Sweden
- Russia
- Poland
- Denmark
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Australia
- Indonesia
- Thailand
- Philippines
- Taiwan
- Vietnam
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of LATAM
The Middle East and Africa
- Saudi Arabia
- UAE
- Israel
- Turkey
- Algeria
- Egypt
- Iran
- Qatar
- Rest of MEA
TABLE OF CONTENTS
1. Pulmonary Embolism Therapeutics Market Overview
1.1. Study Scope
1.2. Market Estimation Years
2. Executive Summary
2.1. Market Snippet
2.1.1. Pulmonary Embolism Therapeutics Market Snippet by Treatment
2.1.2. Pulmonary Embolism Therapeutics Market Snippet by Route of Administration
2.1.3. Pulmonary Embolism Therapeutics Market Snippet by End User
2.1.4. Pulmonary Embolism Therapeutics Market Snippet by Country
2.1.5. Pulmonary Embolism Therapeutics Market Snippet by Region
2.2. Competitive Insights
3. Pulmonary Embolism Therapeutics Key Market Trends
3.1. Pulmonary Embolism Therapeutics Market Drivers
3.1.1. Impact Analysis of Market Drivers
3.2. Pulmonary Embolism Therapeutics Market Restraints
3.2.1. Impact Analysis of Market Restraints
3.3. Pulmonary Embolism Therapeutics Market Opportunities
3.4. Pulmonary Embolism Therapeutics Market Future Trends
4. Pulmonary Embolism Therapeutics Industry Study
4.1. PEST Analysis
4.2. Porter’s Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis
5. Pulmonary Embolism Therapeutics Market: Impact of Escalating Geopolitical Tensions
5.1. Impact of COVID-19 Pandemic
5.2. Impact of Russia-Ukraine War
5.3. Impact of Middle East Conflicts
6. Pulmonary Embolism Therapeutics Market Landscape
6.1. Pulmonary Embolism Therapeutics Market Share Analysis, 2025
6.2. Breakdown Data, by Key Manufacturer
6.2.1. Established Players’ Analysis
6.2.2. Emerging Players’ Analysis
7. Pulmonary Embolism Therapeutics Market – By Treatment
7.1. Overview
7.1.1. Segment Share Analysis, By Treatment, 2025 & 2033 (%)
7.1.2. Direct Oral Anticoagulants (DOACs)
7.1.3. Low-Molecular-Weight Heparin (LMWH)
7.1.4. Unfractionated Heparin
7.1.5. Vitamin K Antagonists
7.1.6. Thrombolytics
7.1.7. Others
8. Pulmonary Embolism Therapeutics Market – By Route of Administration
8.1. Overview
8.1.1. Segment Share Analysis, By Route of Administration, 2025 & 2033 (%)
8.1.2. Oral
8.1.3. Injectables
8.1.4. Others
9. Pulmonary Embolism Therapeutics Market – By End User
9.1. Overview
9.1.1. Segment Share Analysis, By End User, 2025 & 2033 (%)
9.1.2. Hospitals
9.1.3. Specialty Clinics
9.1.4. Retail Pharmacies
9.1.5. Home Healthcare Providers
9.1.6. Others
10. Pulmonary Embolism Therapeutics Market– By Geography
10.1. Introduction
10.1.1. Segment Share Analysis, By Geography, 2025 & 2033 (%)
10.2. North America
10.2.1. Overview
10.2.2. Pulmonary Embolism Therapeutics Key Manufacturers in North America
10.2.3. North America Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
10.2.4. North America Market Size and Forecast, By Treatment, 2020 - 2033 (US$ Million)
10.2.5. North America Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
10.2.6. North America Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
10.2.7. U.S.
10.2.7.1. Overview
10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.2.7.3. U.S. Market Size and Forecast, By Treatment, 2020 - 2033 (US$ Million)
10.2.7.4. U.S. Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
10.2.7.5. U.S. Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
10.2.8. Canada
10.2.8.1. Overview
10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.2.8.3. Canada Market Size and Forecast, By Treatment, 2020 - 2033 (US$ Million)
10.2.8.4. Canada Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
10.2.8.5. Canada Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
10.3. Europe
10.3.1. Overview
10.3.2. Pulmonary Embolism Therapeutics Key Manufacturers in Europe
10.3.3. Europe Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
10.3.4. Europe Market Size and Forecast, By Treatment, 2020 - 2033 (US$ Million)
10.3.5. Europe Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
10.3.6. Europe Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
10.3.7. Germany
10.3.7.1. Overview
10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.3.7.3. Germany Market Size and Forecast, By Treatment, 2020 - 2033 (US$ Million)
10.3.7.4. Germany Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
10.3.7.5. Germany Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
10.3.8. UK
10.3.8.1. Overview
10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.3.8.3. UK Market Size and Forecast, By Treatment, 2020 - 2033 (US$ Million)
10.3.8.4. UK Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
10.3.8.5. UK Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
10.3.9. France
10.3.9.1. Overview
10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.3.9.3. France Market Size and Forecast, By Treatment, 2020 - 2033 (US$ Million)
10.3.9.4. France Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
10.3.9.5. France Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
10.3.10. Italy
10.3.10.1. Overview
10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.3.10.3. Italy Market Size and Forecast, By Treatment, 2020 - 2033 (US$ Million)
10.3.10.4. Italy Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
10.3.10.5. Italy Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
10.3.11. Spain
10.3.11.1. Overview
10.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.3.11.3. Spain Market Size and Forecast, By Treatment, 2020 - 2033 (US$ Million)
10.3.11.4. Spain Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
10.3.11.5. Spain Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
10.3.12. The Netherlands
10.3.12.1. Overview
10.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.3.12.3. The Netherlands Market Size and Forecast, By Treatment, 2020 - 2033 (US$ Million)
10.3.12.4. The Netherlands Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
10.3.12.5. The Netherlands Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
10.3.13. Sweden
10.3.13.1. Overview
10.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.3.13.3. Sweden Market Size and Forecast, By Treatment, 2020 - 2033 (US$ Million)
10.3.13.4. Sweden Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
10.3.13.5. Sweden Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
10.3.14. Russia
10.3.14.1. Overview
10.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.3.14.3. Russia Market Size and Forecast, By Treatment, 2020 - 2033 (US$ Million)
10.3.14.4. Russia Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
10.3.14.5. Russia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
10.3.15. Poland
10.3.15.1. Overview
10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.3.15.3. Poland Market Size and Forecast, By Treatment, 2020 - 2033 (US$ Million)
10.3.15.4. Poland Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
10.3.15.5. Poland Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
10.3.16. Denmark
10.3.16.1. Overview
10.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.3.16.3. Denmark Market Size and Forecast, By Treatment, 2020 - 2033 (US$ Million)
10.3.16.4. Denmark Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
10.3.16.5. Denmark Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
10.3.17. Rest of Europe
10.3.17.1. Overview
10.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.3.17.3. Rest of the Europe Market Size and Forecast, By Treatment, 2020 - 2033 (US$ Million)
10.3.17.4. Rest of the Europe Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
10.3.17.5. Rest of the Europe Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
10.4. Asia Pacific (APAC)
10.4.1. Overview
10.4.2. Pulmonary Embolism Therapeutics Key Manufacturers in Asia Pacific
10.4.3. APAC Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
10.4.4. APAC Market Size and Forecast, By Treatment, 2020 - 2033 (US$ Million)
10.4.5. APAC Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
10.4.6. APAC Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
10.4.7. China
10.4.7.1. Overview
10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.4.7.3. China Market Size and Forecast, By Treatment, 2020 - 2033 (US$ Million)
10.4.7.4. China Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
10.4.7.5. China Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
10.4.8. India
10.4.8.1. Overview
10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.4.8.3. India Market Size and Forecast, By Treatment, 2020 - 2033 (US$ Million)
10.4.8.4. India Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
10.4.8.5. India Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
10.4.9. Japan
10.4.9.1. Overview
10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.4.9.3. Japan Market Size and Forecast, By Treatment, 2020 - 2033 (US$ Million)
10.4.9.4. Japan Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
10.4.9.5. Japan Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
10.4.10. South Korea
10.4.10.1. Overview
10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.4.10.3. South Korea Market Size and Forecast, By Treatment, 2020 - 2033 (US$ Million)
10.4.10.4. South Korea Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
10.4.10.5. South Korea Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
10.4.11. Australia
10.4.11.1. Overview
10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.4.11.3. Australia Market Size and Forecast, By Treatment, 2020 - 2033 (US$ Million)
10.4.11.4. Australia Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
10.4.11.5. Australia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
10.4.12. Indonesia
10.4.12.1. Overview
10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.4.12.3. Indonesia Market Size and Forecast, By Treatment, 2020 - 2033 (US$ Million)
10.4.12.4. Indonesia Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
10.4.12.5. Indonesia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
10.4.13. Thailand
10.4.13.1. Overview
10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.4.13.3. Thailand Market Size and Forecast, By Treatment, 2020 - 2033 (US$ Million)
10.4.13.4. Thailand Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
10.4.13.5. Thailand Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
10.4.14. Philippines
10.4.14.1. Overview
10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.4.14.3. Philippines Market Size and Forecast, By Treatment, 2020 - 2033 (US$ Million)
10.4.14.4. Philippines Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
10.4.14.5. Philippines Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
10.4.15. Taiwan
10.4.15.1. Overview
10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.4.15.3. Taiwan Market Size and Forecast, By Treatment, 2020 - 2033 (US$ Million)
10.4.15.4. Taiwan Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
10.4.15.5. Taiwan Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
10.4.16. Vietnam
10.4.16.1. Overview
10.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.4.16.3. Vietnam Market Size and Forecast, By Treatment, 2020 - 2033 (US$ Million)
10.4.16.4. Vietnam Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
10.4.16.5. Vietnam Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
10.4.17. Rest of APAC
10.4.17.1. Overview
10.4.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.4.17.3. Rest of APAC Market Size and Forecast, By Treatment, 2020 - 2033 (US$ Million)
10.4.17.4. Rest of APAC Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
10.4.17.5. Rest of APAC Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
10.5. Latin America (LATAM)
10.5.1. Overview
10.5.2. Pulmonary Embolism Therapeutics Key Manufacturers in Latin America
10.5.3. LATAM Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
10.5.4. LATAM Market Size and Forecast, By Treatment, 2020 - 2033 (US$ Million)
10.5.5. LATAM Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
10.5.6. LATAM Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
10.5.7. Brazil
10.5.7.1. Overview
10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.5.7.3. Brazil Market Size and Forecast, By Treatment, 2020 - 2033 (US$ Million)
10.5.7.4. Brazil Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
10.5.7.5. Brazil Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
10.5.8. Mexico
10.5.8.1. Overview
10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.5.8.3. Mexico Market Size and Forecast, By Treatment, 2020 - 2033 (US$ Million)
10.5.8.4. Mexico Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
10.5.8.5. Mexico Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
10.5.9. Argentina
10.5.9.1. Overview
10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.5.9.3. Argentina Market Size and Forecast, By Treatment, 2020 - 2033 (US$ Million)
10.5.9.4. Argentina Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
10.5.9.5. Argentina Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
10.5.10. Colombia
10.5.10.1. Overview
10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.5.10.3. Colombia Market Size and Forecast, By Treatment, 2020 - 2033 (US$ Million)
10.5.10.4. Colombia Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
10.5.10.5. Colombia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
10.5.11. Rest of LATAM
10.5.11.1. Overview
10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.5.11.3. Rest of LATAM Market Size and Forecast, By Treatment, 2020 - 2033 (US$ Million)
10.5.11.4. Rest of LATAM Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
10.5.11.5. Rest of LATAM Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
10.6. Middle East and Africa (MEA)
10.6.1. Overview
10.6.2. Pulmonary Embolism Therapeutics Key Manufacturers in Middle East and Africa
10.6.3. MEA Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
10.6.4. MEA Market Size and Forecast, By Treatment, 2020 - 2033 (US$ Million)
10.6.5. MEA Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
10.6.6. MEA Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
10.6.7. Saudi Arabia
10.6.7.1. Overview
10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.6.7.3. Saudi Arabia Market Size and Forecast, By Treatment, 2020 - 2033 (US$ Million)
10.6.7.4. Saudi Arabia Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
10.6.7.5. Saudi Arabia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
10.6.8. UAE
10.6.8.1. Overview
10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.6.8.3. UAE Market Size and Forecast, By Treatment, 2020 - 2033 (US$ Million)
10.6.8.4. UAE Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
10.6.8.5. UAE Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
10.6.9. Israel
10.6.9.1. Overview
10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.6.9.3. Israel Market Size and Forecast, By Treatment, 2020 - 2033 (US$ Million)
10.6.9.4. Israel Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
10.6.9.5. Israel Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
10.6.10. Turkey
10.6.10.1. Overview
10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.6.10.3. Turkey Market Size and Forecast, By Treatment, 2020 - 2033 (US$ Million)
10.6.10.4. Turkey Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
10.6.10.5. Turkey Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
10.6.11. Algeria
10.6.11.1. Overview
10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.6.11.3. Algeria Market Size and Forecast, By Treatment, 2020 - 2033 (US$ Million)
10.6.11.4. Algeria Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
10.6.11.5. Algeria Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
10.6.12. Egypt
10.6.12.1. Overview
10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.6.12.3. Egypt Market Size and Forecast, By Treatment, 2020 - 2033 (US$ Million)
10.6.12.4. Egypt Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
10.6.12.5. Egypt Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
10.6.13. Iran
10.6.13.1. Overview
10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.6.13.3. Iran Market Size and Forecast, By Treatment, 2020 - 2033 (US$ Million)
10.6.13.4. Iran Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
10.6.13.5. Iran Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
10.6.14. Qatar
10.6.14.1. Overview
10.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.6.14.3. Qatar Market Size and Forecast, By Treatment, 2020 - 2033 (US$ Million)
10.6.14.4. Qatar Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
10.6.14.5. Qatar Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
10.6.15. Rest of MEA
10.6.15.1. Overview
10.6.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.6.15.3. Rest of MEA Market Size and Forecast, By Treatment, 2020 - 2033 (US$ Million)
10.6.15.4. Rest of MEA Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
10.6.15.5. Rest of MEA Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11. Key Vendor Analysis- Pulmonary Embolism Therapeutics Industry
11.1. Competitive Benchmarking
11.1.1. Competitive Dashboard
11.1.2. Competitive Positioning
11.2. Company Profiles
11.2.1. Bayer AG
11.2.2. Johnson & Johnson
11.2.3. Pfizer Inc.
11.2.4. Bristol Myers Squibb
11.2.5. Daiichi Sankyo Co., Ltd.
11.2.6. Sanofi
11.2.7. Boehringer Ingelheim
11.2.8. Viatris Inc.
11.2.9. Novartis AG
11.2.10. Eli Lilly and Company
11.2.11. Amgen Inc.
11.2.12. Astellas Pharma Inc.
11.2.13. F. Hoffmann-La Roche Ltd.
11.2.14. Gilead Sciences Inc.
11.2.15. Takeda Pharmaceutical Company Limited
11.2.16. Others
12. 360 Degree AnalystView
13. Appendix
13.1. Research Methodology
13.2. References
13.3. Abbreviations
13.4. Disclaimer
13.5. Contact Us
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL PULMONARY EMBOLISM THERAPEUTICS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
- Bayer AG
- Johnson & Johnson
- Pfizer Inc.
- Bristol Myers Squibb
- Daiichi Sankyo Co., Ltd.
- Sanofi
- Boehringer Ingelheim
- Viatris Inc.
- Novartis AG
- Eli Lilly and Company
- Amgen Inc.
- Astellas Pharma Inc.
- Hoffmann-La Roche Ltd.
- Gilead Sciences Inc.
- Takeda Pharmaceutical Company Limited
- Others
GLOBAL PULMONARY EMBOLISM THERAPEUTICS MARKET, BY TREATMENT- MARKET ANALYSIS, 2020 - 2033
- Direct Oral Anticoagulants (DOACs)
- Low-Molecular-Weight Heparin (LMWH)
- Unfractionated Heparin
- Vitamin K Antagonists
- Thrombolytics
- Others
GLOBAL PULMONARY EMBOLISM THERAPEUTICS MARKET, BY ROUTE OF ADMINISTATION- MARKET ANALYSIS, 2020 - 2033
- Oral
- Injectables
- Others
GLOBAL PULMONARY EMBOLISM THERAPEUTICS MARKET, BY END USER- MARKET ANALYSIS, 2020 - 2033
- Hospitals
- Specialty Clinics
- Retail Pharmacies
- Home Healthcare Providers
- Others
GLOBAL PULMONARY EMBOLISM THERAPEUTICS MARKET, BY REGION- MARKET ANALYSIS, 2020 - 2033
North America
- U.S.
- Canada
Europe
- Germany
- UK
- France
- Italy
- Spain
- The Netherlands
- Sweden
- Russia
- Poland
- Denmark
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Australia
- Indonesia
- Thailand
- Philippines
- Taiwan
- Vietnam
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of LATAM
The Middle East and Africa
- Saudi Arabia
- UAE
- Israel
- Turkey
- Algeria
- Egypt
- Iran
- Qatar
- Rest of MEA
Related Reports
Credibility and Certifications
Trusted Insights, Certified Excellence! Coherent Market Insights is a certified data advisory and business consulting firm recognized by global institutes.
ISO 9001:2015
ESOMAR Corporate
GDPR Compliance
D-U-N-S Registered
BBB Accreditation
MRS
